Δ-8-Tetrahydrocannabinol

Sources

7 strong · 24 moderate · 2 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

159/159 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	low
Low	5–15 mg	5–15 mg	low
Common	15–40 mg	15–40 mg	low
Strong	40–80 mg	40–80 mg	low
Heavy	80+ mg	80+ mg	low
Editorial	No published human dose-response data for Δ8-THC. Oral doses inferred from: (1) Mechoulam pediatric antiemetic dose of 18 mg/m² ≈ 10-30 mg; (2) consumer product serving sizes of 5-40 mg (Ray et al. 2022, noting label accuracy is unreliable); (3) structural analog inference from Δ9-THC oral doses × ~2-3x potency factor (Tagen & Klumpers 2022 estimate Δ8-THC ≈ 2/3 potency of Δ9-THC). Ranges widened conservatively to account for absent controlled data. SAFETY-CRITICAL: these are editorial proposals requiring human review.
	ReasoningReasoning No published human dose-response data for Δ8-THC. Oral doses inferred from: (1) Mechoulam pediatric antiemetic dose of 18 mg/m² ≈ 10-30 mg; (2) consumer product serving sizes of 5-40 mg (Ray et al. 2022, noting label accuracy is unreliable); (3) structural analog inference from Δ9-THC oral doses × ~2-3x potency factor (Tagen & Klumpers 2022 estimate Δ8-THC ≈ 2/3 potency of Δ9-THC). Ranges widened conservatively to account for absent controlled data. SAFETY-CRITICAL: these are editorial proposals requiring human review. Evidence basis: structural_analogy

vaporizedtrace

Field	Published	AI Proposed	Confidence
Threshold	2 mg	2 mg	low
Low	2–5 mg	2–5 mg	low
Common	5–15 mg	5–15 mg	low
Strong	15–30 mg	15–30 mg	low
Heavy	30+ mg	30+ mg	low
Editorial	No published human dose-response data for Δ8-THC via inhalation. Vaporized doses inferred entirely from structural analog inference: Δ9-THC inhalation doses × ~2-3x potency factor. Johns Hopkins vaporized Δ8-THC trial (NCT05287256, Spindle et al. 2025) has been completed but full dose-response data await publication. Ranges widened conservatively. SAFETY-CRITICAL: these are editorial proposals requiring human review.
	ReasoningReasoning No published human dose-response data for Δ8-THC via inhalation. Vaporized doses inferred entirely from structural analog inference: Δ9-THC inhalation doses × ~2-3x potency factor. Johns Hopkins vaporized Δ8-THC trial (NCT05287256, Spindle et al. 2025) has been completed but full dose-response data await publication. Ranges widened conservatively. SAFETY-CRITICAL: these are editorial proposals requiring human review. Evidence basis: structural_analogy

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	30–120 minutes	30–120 minutes	low
Editorial	Inferred from Δ9-THC oral onset profile. Δ8-THC rat PK shows Tmax ~6h for MCT oil, ~0.67-1h for nanoemulsion (Senetra et al. 2026; Tagen et al. 2023), but human subjective onset is expected to follow Δ9-THC oral kinetics. No controlled human time-course data for Δ8-THC.
	ReasoningReasoning Inferred from Δ9-THC oral onset profile. Δ8-THC rat PK shows Tmax ~6h for MCT oil, ~0.67-1h for nanoemulsion (Senetra et al. 2026; Tagen et al. 2023), but human subjective onset is expected to follow Δ9-THC oral kinetics. No controlled human time-course data for Δ8-THC. Evidence basis: structural_analogy
Come uptrace	30–60 minutes	30–60 minutes	low
Editorial	Structural analog inference from Δ9-THC oral come-up. No human Δ8-THC time-course data published.
	ReasoningReasoning Structural analog inference from Δ9-THC oral come-up. No human Δ8-THC time-course data published. Evidence basis: structural_analogy
Peaktrace	2–4 hours	2–4 hours	low
Editorial	Structural analog inference from Δ9-THC oral peak duration. Active metabolite 11-OH-Δ8-THC may extend perceived peak after oral dosing. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC oral peak duration. Active metabolite 11-OH-Δ8-THC may extend perceived peak after oral dosing. No human Δ8-THC data. Evidence basis: structural_analogy
Offsettrace	2–4 hours	2–4 hours	low
Editorial	Structural analog inference from Δ9-THC oral offset. High lipophilicity and tissue sequestration support gradual decline. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC oral offset. High lipophilicity and tissue sequestration support gradual decline. No human Δ8-THC data. Evidence basis: structural_analogy
Totaltrace	4–8 hours	4–8 hours	low
Editorial	Structural analog inference from Δ9-THC oral total subjective duration. Reflects onset through offset only — does not include aftereffects or pharmacological elimination. No human Δ8-THC time-course data.
	ReasoningReasoning Structural analog inference from Δ9-THC oral total subjective duration. Reflects onset through offset only — does not include aftereffects or pharmacological elimination. No human Δ8-THC time-course data. Evidence basis: structural_analogy
After effectstrace	2–12 hours	2–12 hours	low
Editorial	Structural analog inference from Δ9-THC. Wide range reflects variable individual metabolism and lipophilic tissue redistribution. Residual sedation and mild appetite effects may persist. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC. Wide range reflects variable individual metabolism and lipophilic tissue redistribution. Residual sedation and mild appetite effects may persist. No human Δ8-THC data. Evidence basis: structural_analogy

vaporized

Field	Published	AI Proposed	Confidence
Onsettrace	1–5 minutes	1–5 minutes	low
Editorial	Structural analog inference from Δ9-THC inhalation onset. Rapid pulmonary absorption bypasses first-pass metabolism. No human Δ8-THC time-course data, though Johns Hopkins vaporized trial (Spindle 2025) is completed.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation onset. Rapid pulmonary absorption bypasses first-pass metabolism. No human Δ8-THC time-course data, though Johns Hopkins vaporized trial (Spindle 2025) is completed. Evidence basis: structural_analogy
Come uptrace	5–10 minutes	5–10 minutes	low
Editorial	Structural analog inference from Δ9-THC inhalation come-up. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation come-up. No human Δ8-THC data. Evidence basis: structural_analogy
Peaktrace	15–45 minutes	15–45 minutes	low
Editorial	Structural analog inference from Δ9-THC inhalation peak. Less first-pass metabolite contribution than oral route. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation peak. Less first-pass metabolite contribution than oral route. No human Δ8-THC data. Evidence basis: structural_analogy
Offsettrace	1–2 hours	1–2 hours	low
Editorial	Structural analog inference from Δ9-THC inhalation offset. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation offset. No human Δ8-THC data. Evidence basis: structural_analogy
Totaltrace	1–4 hours	1–4 hours	low
Editorial	Structural analog inference from Δ9-THC inhalation total subjective duration. Shorter than oral due to absence of sustained first-pass metabolite generation. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation total subjective duration. Shorter than oral due to absence of sustained first-pass metabolite generation. No human Δ8-THC data. Evidence basis: structural_analogy
After effectstrace	1–6 hours	1–6 hours	low
Editorial	Structural analog inference from Δ9-THC inhalation aftereffects. Lipophilic redistribution from tissue stores may produce residual sedation. No human Δ8-THC data.
	ReasoningReasoning Structural analog inference from Δ9-THC inhalation aftereffects. Lipophilic redistribution from tissue stores may produce residual sedation. No human Δ8-THC data. Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	low	low	medium
Chronic	low	low	medium
Organs Affected	CNS, cardiovascular	CNS, cardiovascular	medium
Editorial	Work-notes specify acute: low, chronic: low-to-moderate. Applying evidence discount rule: chronic downgraded from 'low-to-moderate' to 'low' because organ damage evidence is absent for the pure compound — the elevated chronic concern (product contamination) is a product-level risk, not pharmacology-level. Acute toxicity supported by FAERS case series (Simon et al. 2023) and CDC poison control data (2,362 exposures). No LD50 data, no human fatalities, very high therapeutic index by class.
	ReasoningReasoning Work-notes specify acute: low, chronic: low-to-moderate. Applying evidence discount rule: chronic downgraded from 'low-to-moderate' to 'low' because organ damage evidence is absent for the pure compound — the elevated chronic concern (product contamination) is a product-level risk, not pharmacology-level. Acute toxicity supported by FAERS case series (Simon et al. 2023) and CDC poison control data (2,362 exposures). No LD50 data, no human fatalities, very high therapeutic index by class. Evidence basis: published_case_series

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	low	low	medium
Psychological	moderate	moderate	medium
Compulsive Redosing	low	low	medium
Dose Escalation	moderate	moderate	medium
Editorial	Physical dependence demonstrated substance-specifically in rodents (Vanegas et al. 2022: rimonabant-precipitated withdrawal after Δ8-THC ≥10 mg/kg BID × 6 days). Psychological dependence and CUD criteria inferred from Δ9-THC literature via structural analogy. Work-notes specify physical: low-to-moderate, psychological: moderate; physical rounded to 'low' per evidence discount (rodent data only, no human characterization).
	ReasoningReasoning Physical dependence demonstrated substance-specifically in rodents (Vanegas et al. 2022: rimonabant-precipitated withdrawal after Δ8-THC ≥10 mg/kg BID × 6 days). Psychological dependence and CUD criteria inferred from Δ9-THC literature via structural analogy. Work-notes specify physical: low-to-moderate, psychological: moderate; physical rounded to 'low' per evidence discount (rodent data only, no human characterization). Evidence basis: animal_study

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	mild	mild	low
Symptoms	Irritability, Sleep disturbance, Decreased appetite, Dysphoria, Jumping (rodent), Paw tremors (rodent), Altered marble-burying behavior (rodent)	Irritability, Sleep disturbance, Decreased appetite, Dysphoria, Jumping (rodent), Paw tremors (rodent), Altered marble-burying behavior (rodent)	low
Fatal	No	No	low
Medical Supervision	Not required	Not required	low
Editorial	Somatic withdrawal signs demonstrated in rodents with rimonabant-precipitated withdrawal (Vanegas et al. 2022). Human withdrawal symptoms (irritability, sleep disturbance, decreased appetite, dysphoria) and timeline (onset 1-2 days, duration 1-2 weeks) are entirely inferred from Δ9-THC cannabis withdrawal literature. Severity downgraded from 'mild-to-moderate' to 'mild' per evidence discount — no human clinical characterization exists for Δ8-THC-specific withdrawal.
	ReasoningReasoning Somatic withdrawal signs demonstrated in rodents with rimonabant-precipitated withdrawal (Vanegas et al. 2022). Human withdrawal symptoms (irritability, sleep disturbance, decreased appetite, dysphoria) and timeline (onset 1-2 days, duration 1-2 weeks) are entirely inferred from Δ9-THC cannabis withdrawal literature. Severity downgraded from 'mild-to-moderate' to 'mild' per evidence discount — no human clinical characterization exists for Δ8-THC-specific withdrawal. Evidence basis: animal_study

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	medium
Half-life	7 days	7 days	medium
Full Reset	21 days	21 days	medium
Cross-tolerances	Δ9-THC, WIN 55,212-2, Synthetic cannabinoids (CB1 agonists)	Δ9-THC, WIN 55,212-2, Synthetic cannabinoids (CB1 agonists)	medium
Editorial	Tolerance buildup is substance-specific (Vanegas et al. 2022: tolerance to tetrad endpoints in mice). Half-life and full reset values are inferred from Δ9-THC class data — no human tolerance timeline data exist for Δ8-THC. Cross-tolerance confirmed substance-specifically for WIN 55,212-2; Δ9-THC cross-tolerance inferred from shared CB1 mechanism and discriminative stimulus substitution.
	ReasoningReasoning Tolerance buildup is substance-specific (Vanegas et al. 2022: tolerance to tetrad endpoints in mice). Half-life and full reset values are inferred from Δ9-THC class data — no human tolerance timeline data exist for Δ8-THC. Cross-tolerance confirmed substance-specifically for WIN 55,212-2; Δ9-THC cross-tolerance inferred from shared CB1 mechanism and discriminative stimulus substitution. Evidence basis: animal_study

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
psychiatric History of psychotic disorderstrace	absolute	absolute	low
Editorial	Class inference from Δ9-THC. CB1 agonism is the established mechanism for cannabis-induced psychosis. Δ8-THC shares this mechanism with ~6-fold lower CB1 affinity but sufficient agonist activity to produce psychoactive effects.
	ReasoningReasoning Class inference from Δ9-THC. CB1 agonism is the established mechanism for cannabis-induced psychosis. Δ8-THC shares this mechanism with ~6-fold lower CB1 affinity but sufficient agonist activity to produce psychoactive effects.
cardiovascular Cardiovascular diseasetrace	relative	relative	low
Editorial	Class inference from Δ9-THC. CB1-mediated cardiovascular effects are well-documented for Δ9-THC and expected to apply to Δ8-THC given shared receptor pharmacology.
	ReasoningReasoning Class inference from Δ9-THC. CB1-mediated cardiovascular effects are well-documented for Δ9-THC and expected to apply to Δ8-THC given shared receptor pharmacology.
pregnancy breastfeeding Pregnancy and lactationtrace	absolute	absolute	low
Editorial	Class inference from Δ9-THC. Lipophilicity (Vd = 108 L/kg in rats) ensures extensive tissue distribution including placental and mammary transfer. CB1 agonism during development is a recognized teratogenic risk factor.
	ReasoningReasoning Class inference from Δ9-THC. Lipophilicity (Vd = 108 L/kg in rats) ensures extensive tissue distribution including placental and mammary transfer. CB1 agonism during development is a recognized teratogenic risk factor.
other Anticoagulant therapy (warfarin)trace	relative	relative	medium
Editorial	CYP profile inferred from Δ9-THC structural analogy (Nachnani et al. 2024). Warfarin interaction is a narrow-therapeutic-index safety concern warranting relative contraindication despite indirect evidence.
	ReasoningReasoning CYP profile inferred from Δ9-THC structural analogy (Nachnani et al. 2024). Warfarin interaction is a narrow-therapeutic-index safety concern warranting relative contraindication despite indirect evidence.
hepatic Hepatic impairmenttrace	relative	relative	low
Editorial	Class inference from Δ9-THC and Δ8-THC rodent PK data showing extensive first-pass metabolism (oral bioavailability ~3%, clearance 5.6 L/h/kg). Hepatic impairment would predictably alter exposure.
	ReasoningReasoning Class inference from Δ9-THC and Δ8-THC rodent PK data showing extensive first-pass metabolism (oral bioavailability ~3%, clearance 5.6 L/h/kg). Hepatic impairment would predictably alter exposure.
age Pediatric populationstrace	absolute	absolute	high
Editorial	Substance-specific evidence from CDC HAN 00451 (2,362 exposures, 41% pediatric), Babalonis et al. 2021 (LOC in children), and Garay et al. 2025 (toxic doses in children <6). This is the highest-confidence contraindication for Δ8-THC.
	ReasoningReasoning Substance-specific evidence from CDC HAN 00451 (2,362 exposures, 41% pediatric), Babalonis et al. 2021 (LOC in children), and Garay et al. 2025 (toxic doses in children <6). This is the highest-confidence contraindication for Δ8-THC.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1800–7200 sec(i=0.10)	1800–7200 sec(i=0.10)	low
Editorial	All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence.
	ReasoningReasoning All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence. Evidence basis: structural_analogy
Come uptrace	1800–3600 sec(i=0.40)	1800–3600 sec(i=0.40)	low
Editorial	All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence.
	ReasoningReasoning All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence. Evidence basis: structural_analogy
Peaktrace	7200–14400 sec(i=1.00)	7200–14400 sec(i=1.00)	low
Editorial	All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence.
	ReasoningReasoning All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence. Evidence basis: structural_analogy
Resolutiontrace	7200–14400 sec(i=0.50)	7200–14400 sec(i=0.50)	low
Editorial	All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence.
	ReasoningReasoning All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence. Evidence basis: structural_analogy
Afterglowtrace	7200–43200 sec(i=0.15)	7200–43200 sec(i=0.15)	low
Editorial	All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence.
	ReasoningReasoning All oral timeline phases inferred from Δ9-THC oral duration profile via structural analogy. No controlled human time-course data for Δ8-THC have been published. Δ8-THC shares identical metabolic pathway (CYP3A4/2C9 → 11-OH-Δ8-THC active metabolite) and comparable lipophilicity, supporting analogous oral kinetics. Phase durations widened to reflect absent direct evidence. Evidence basis: structural_analogy

vaporized

Field	Published	AI Proposed	Confidence
Onsettrace	60–300 sec(i=0.30)	60–300 sec(i=0.30)	low
Editorial	All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism.
	ReasoningReasoning All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism. Evidence basis: structural_analogy
Come uptrace	300–600 sec(i=0.70)	300–600 sec(i=0.70)	low
Editorial	All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism.
	ReasoningReasoning All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism. Evidence basis: structural_analogy
Peaktrace	900–2700 sec(i=1.00)	900–2700 sec(i=1.00)	low
Editorial	All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism.
	ReasoningReasoning All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism. Evidence basis: structural_analogy
Resolutiontrace	3600–7200 sec(i=0.40)	3600–7200 sec(i=0.40)	low
Editorial	All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism.
	ReasoningReasoning All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism. Evidence basis: structural_analogy
Afterglowtrace	3600–21600 sec(i=0.10)	3600–21600 sec(i=0.10)	low
Editorial	All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism.
	ReasoningReasoning All vaporized timeline phases inferred from Δ9-THC inhalation duration profile via structural analogy. No controlled human time-course data for vaporized Δ8-THC published, though Johns Hopkins trial (Spindle et al. 2025, NCT05287256) compared vaporized Δ8-THC to Δ9-THC — full data await publication. Rapid onset reflects pulmonary absorption bypassing first-pass metabolism. Evidence basis: structural_analogy

Dose Tier Summaries

thresholdtrace

low

Minimal perceptible effects emerge as a faint shift in mood — a subtle brightening or softening of emotional tone that may take 30 minutes or more to notice via oral administration. A gentle body warmth or slight heaviness may be felt, but physical effects are barely distinguishable from baseline. Cognitive function remains largely intact. Appetite may increase marginally. Tolerant cannabis users may find threshold doses imperceptible. The experience serves primarily as a calibration point for individual sensitivity rather than a meaningful psychoactive event. Oral onset is slow (up to 2 hours). Do not redose before confirming full onset, as stacking threshold doses can produce unexpectedly strong effects.

Editorial

No published human dose-response data for Δ8-THC. Threshold description inferred from Δ9-THC threshold experience profile, adjusted for Δ8-THC's ~2/3 relative potency and consumer reports of 'clearer-headed' character (Kruger & Kruger 2022).

Reasoning

Evidence basis: structural_analogy

lighttrace

low

Mild relaxation and subtle euphoria become clearly noticeable. A light body high develops — gentle warmth and slight muscle relaxation without heaviness. Appetite enhancement begins, and dry mouth may appear. The mood shift is pleasant but easily managed. Cognitive clarity is largely preserved at this level, distinguishing Δ8-THC from equivalent subjective doses of Δ9-THC. Thought deceleration is minimal. Focus suppression is slight — most tasks remain manageable. Anxiety is unlikely; anxiolytic effects are more typical. Social interaction feels natural. Duration commitment is modest (1–4 hours inhaled, 4–6 hours oral). Sleep may come more easily at the tail end of the experience.

Editorial

Inferred from Δ9-THC light-dose experience, adjusted for Δ8-THC's lower CB1 affinity and consumer survey data describing 'lighter' and 'clearer-headed' effects (Kruger & Kruger 2022). No controlled human dose-response data.

Reasoning

Evidence basis: structural_analogy

commontrace

low

Clear cannabinoid intoxication is present. Euphoria and relaxation are the dominant features — a warm, pleasant cognitive glow paired with noticeable body high and muscle relaxation. Appetite enhancement is reliable. Nausea suppression is effective at this range, consistent with Mechoulam's antiemetic findings. Cognitive effects become apparent: mild thought deceleration, short-term memory suppression, and subtle time alteration. Focus suppression makes complex tasks more difficult. These cognitive changes are consistently described as less impairing than equivalent Δ9-THC doses. Humor enhancement and music enhancement may emerge. Anxiolytic effects are typical at this tier. Motor control impairment is mild but present — driving is unsafe. Dry mouth is common. Sedation increases toward the offset phase.

Editorial

Common-dose profile synthesized from Kruger & Kruger 2022 consumer survey (relaxation, euphoria, pain relief, anxiolysis as top effects; 'clearer-headed' than Δ9-THC), Mechoulam 1995 antiemetic data, and Δ9-THC common-dose class inference. Dose values themselves lack controlled human data.

Reasoning

Evidence basis: structural_analogy

strongtrace

low

Pronounced intoxication with significant sedation and strong euphoria. Body high is heavy — deep muscle relaxation and bodily heaviness dominate the physical experience. Cognitive impairment is notable: marked memory suppression, meaningful thought deceleration, and time alteration become difficult to ignore. Anxiety and paranoia become possible at this tier, particularly in predisposed individuals or those with low cannabinoid tolerance, though rates remain lower than with equivalent Δ9-THC doses. Motor control impairment is significant — coordination is visibly affected. Appetite enhancement is strong. Physical fatigue and sedation increase throughout the experience. Functional impairment is substantial; this tier commits the user to several hours of incapacity. Oral administration at this level carries risk of unexpectedly prolonged duration.

Editorial

Strong-dose profile inferred from Δ9-THC strong-dose experience, CDC/FAERS adverse event data (anxiety, dizziness, confusion at high doses), and Kruger 2022 survey noting lower anxiety/paranoia rates than Δ9-THC. No controlled Δ8-THC dose-response data.

Reasoning

Evidence basis: structural_analogy

heavytrace

low

Intense sedation dominates. Confusion and disorientation are likely. Cognitive impairment is severe — memory suppression is near-total for the peak period, and thought disorganization may occur. Rare visual or auditory disturbances have been reported at this level in adverse event data, though frank hallucinations remain uncommon. Anxiety and paranoia risk is elevated, particularly in cannabis-naive individuals. Nausea may paradoxically emerge despite Δ8-THC's antiemetic properties. Dizziness is common. Tachycardia may be noticeable and distressing. Loss of consciousness has been documented in pediatric cases at high weight-adjusted doses. This tier is not recommended. The experience is unlikely to be pleasant and carries meaningful physical risk. Oral administration at heavy doses, especially with slow-onset formulations, risks hours of incapacitation with no ability to reduce intensity.

Editorial

Heavy-dose profile drawn from CDC HAN 00451 adverse event data (hallucinations, vomiting, tremor, confusion, LOC in pediatric cases), FAERS data (55% required intervention), and Δ9-THC heavy-dose class inference. This tier represents adverse event territory rather than intended use.

Reasoning

Evidence basis: structural_analogy

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +0 / −0 citations

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

7 strong · 24 moderate · 2 weak

[1]
strong
Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC
Tagen M, Klumpers LE · 2022 · British Journal of Pharmacology
doi.org/10.1111/bph.15865 pubmed 35523678no claims checked
[2]
moderate
Minnesota wild hemp: a crucial botanical source in early cannabinoid discovery
Filer CN · 2020 · Journal of Cannabis Research
doi.org/10.1186/s42238-020-00031-3 pubmed 33526126no claims checked
[3]
strong
Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol
Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA · 2024 · Molecules
doi.org/10.3390/molecules29061249 pubmed 38542886no claims checked
[4]
moderate
An efficient new cannabinoid antiemetic in pediatric oncology
Abrahamov A, Abrahamov A, Mechoulam R · 1995 · Life Sciences
pubmed 7776837no claims checked
[5]
moderate
Δ8-THC: Legal Status, Widespread Availability, and Safety Concerns
Babalonis S, Raup-Konsavage WM, Akpunonu PD, Balla A, Vrana KE · 2021 · Cannabis and Cannabinoid Research
doi.org/10.1089/can.2021.0097 pubmed 34662224no claims checked
[6]
moderate
Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats
Yamaguchi T, Shoyama Y, Watanabe S, Yamamoto T · 2001 · Brain Research
pubmed 11166698no claims checked
[7]
moderate
Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice
Vanegas SO, Reck AM, Rodriguez CE, Marusich JA, Yassin O, Sotzing G, Wiley JL, Kinsey SG · 2022 · Drug and Alcohol Dependence
doi.org/10.1016/j.drugalcdep.2022.109640 pubmed 36179506no claims checked
[8]
moderate
Delta-8-THC: Delta-9-THC's nicer younger sibling?
Kruger JS, Kruger DJ · 2022 · Journal of Cannabis Research
doi.org/10.1186/s42238-021-00115-8 pubmed 34980292no claims checked
[9]
moderate
Delta-8 Tetrahydrocannabinol Product Impurities
Ray CL, Bylo MP, Pescaglia J, Gawenis JA, Greenlief CM · 2022 · Molecules
doi.org/10.3390/molecules27206924 pubmed 36296514no claims checked
[10]
strong
A within-subject cross-over trial comparing the acute effects of vaporized delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults
Spindle TR, Zamarripa CA, Schriefer D, Cone EJ, Winecker R, Flegel R, Hayes E, Davis LS, Kuntz D, Vandrey R · 2025 · Drug and Alcohol Dependence
doi.org/10.1016/j.drugalcdep.2025.112684 pubmed 40334328no claims checked
[11]
strong
A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults
Zamarripa CA, Spindle TR, Schriefer D, Cone EJ, Winecker RE, Flegel R, Hayes E, Davis LS, Kuntz D, Vandrey R · 2025 · Drug and Alcohol Dependence
doi.org/10.1016/j.drugalcdep.2025.112676 pubmed 40288059no claims checked
[12]
weak
5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC
US Food and Drug Administration · 2022
linkno claims checked
[13]
weak
CDC Health Advisory: Increases in Availability of Cannabis Products Containing Delta-8 THC and Reported Cases of Adverse Events (HAN 00451)
Centers for Disease Control and Prevention · 2021
linkno claims checked
[14]
moderate
Patterns of delta 8 THC and cannabis uptake in Nebraska: A cannabis prohibition state
Humeniuk R, Habecker P, Cooper-Ohm S, Bevins RA · 2024 · International Journal on Drug Policy
doi.org/10.1016/j.drugpo.2024.104400 pubmed 38554564no claims checked
[15]
moderate
Enhanced solubility, stability, and transcorneal permeability of delta-8-tetrahydrocannabinol in the presence of cyclodextrins
Hippalgaonkar K, Gul W, ElSohly MA, Repka MA, Majumdar S · 2011 · AAPS PharmSciTech
doi.org/10.1208/s12249-011-9639-5 pubmed 21637944no claims checked
[16]
moderate
Easy and Accessible Synthesis of Cannabinoids from CBD
Capucciati A, Casali E, Bini A, Doria F, Merli D, Porta A · 2024 · Journal of Natural Products
doi.org/10.1021/acs.jnatprod.3c01117 pubmed 38427968no claims checked
[17]
moderate
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR · 1991 · Journal of Neuroscience
doi.org/10.1523/jneurosci.11-02-00563.1991 pubmed 1992016no claims checked
[18]
moderate
Pharmacokinetic study of delta-8-tetrahydrocannabinol in male rats using a validated bioanalytical method
Senetra AS, Mukhopadhyay S, Chiang YH, Kuntz MA, Kanumuri SRR, Zequeira S, Setlow B, McCurdy CR, Sharma A · 2026 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bkaf105 pubmed 41405849no claims checked
[19]
moderate
Pharmacokinetics of Two Nanoemulsion Formulations of Δ8-Tetrahydrocannabinol in Rats
Tagen M, Klumpers LE, Peshkovsky A · 2023 · AAPS PharmSciTech
doi.org/10.1208/s12249-023-02699-1 pubmed 37989959no claims checked
[20]
moderate
Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain
Moore CF, Weerts EM, Kulpa J, Schwotzer D, Dye W, Jantzi J, McDonald JD, Lefever TW, Bonn-Miller MO · 2023 · Cannabis and Cannabinoid Research
doi.org/10.1089/can.2023.0066 pubmed 37721988no claims checked
[21]
moderate
LC-MS-MS quantification of Δ8-THC, Δ9-THC, THCV isomers and their main metabolites in human plasma
Sempio C, Campos-Palomino J, Klawitter J, Harrison A, Peters EN, MacNair L, Haghdoost M, Bonn-Miller M, Babalonis S, Huestis MA, Christians U, Klawitter J · 2024 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bkae048 pubmed 38836589no claims checked
[22]
strong
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis
Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, Tegeler K, Trite T, Raup-Konsavage WM, Vrana KE · 2024 · Frontiers in Pharmacology
doi.org/10.3389/fphar.2024.1282831 pubmed 38868665no claims checked
[23]
moderate
Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
Wiley JL, Marusich JA, Blough BE, et al. · 2024 · Progress in neuro-psychopharmacology & biological psychiatry
doi.org/10.1016/j.pnpbp.2024.110984 pubmed 38417478no claims checked
[24]
moderate
Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues
Griffin G, Williams S, Aung MM, Razdan RK, Martin BR, Abood ME · 2001 · British Journal of Pharmacology
pubmed 11159703no claims checked
[25]
strong
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U · 2003 · JAMA
pubmed 14519710no claims checked
[26]
strong
Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review
Almuntashiri N, El Sharazly BM, Carter WG · 2025 · Biomolecules
doi.org/10.3390/biom15060816 pubmed 40563456no claims checked
[27]
moderate
Cannabinoids in glaucoma: a primary screening procedure.
Elsohly MA, Harland E, Murphy JC, Wirth P, Waller CW · 1981 · Journal of clinical pharmacology
pubmed 6271842no claims checked
[28]
moderate
Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit
ElSohly MA, Harland EC, Benigni DA, Waller CW · 1984 · Current Eye Research
pubmed 6329602no claims checked
[29]
moderate
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation
Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, Thakur GA, Kelly MEM · 2020 · Molecules
doi.org/10.3390/molecules25020417 pubmed 31968549no claims checked
[30]
moderate
U.S. State Marijuana and Delta-8-Tetrahydrocannabinol Laws and Delta-8-Tetrahydrocannabinol Use
Satybaldiyeva N, Yang KH, Kepner WE, Leas EC · 2025 · American Journal of Preventive Medicine
doi.org/10.1016/j.amepre.2025.108026 pubmed 40900067no claims checked
[31]
moderate
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Simon TA, Simon JH, Heaning EG, Gomez-Caminero A, Marcu JP · 2023 · Drug, Healthcare and Patient Safety
doi.org/10.2147/dhps.s391857 pubmed 36742440no claims checked
[32]
moderate
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers
Burgess A, Hays HL, Badeti J, Spiller HA, Rine NI, Gaw CE, Ding K, Smith GA · 2024 · Clinical Toxicology
doi.org/10.1080/15563650.2024.2340115 pubmed 38686923no claims checked
[33]
moderate
Investigation of the toxic dose of ingested delta-8 tetrahydrocannabinol among young children
Garay RS, Hays HL, Badeti J, Rine NI, Gaw CE, Middelberg LK, Smith GA · 2025 · Injury Epidemiology
doi.org/10.1186/s40621-025-00617-6 pubmed 41029884no claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

120 links · 120 approved · 0 audited0/120 with evidence basis

Δ-8-Tetrahydrocannabinol

Value Provenance

Dosing

oraltrace →

vaporizedtrace →

Duration

oral

vaporized

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

vaporized

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

oraltrace

vaporizedtrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace